# A Study of HB0045 Injection in Patients With Advanced Solid Tumors

> **NCT06056323** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Huaota Biopharmaceutical Co., Ltd.** · enrollment: 71 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** HB0045 Drug Product

## Key facts

- **NCT ID:** NCT06056323
- **Lead sponsor:** Shanghai Huaota Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-18
- **Primary completion:** 2025-09-19
- **Final completion:** 2026-03-19
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2023-10-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06056323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06056323, "A Study of HB0045 Injection in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06056323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*